Jagadeesh Bayry: Molecular and Genetic Mechanisms of VITT
Jagadeesh Bayry, Professor and Head of Department at the Indian Institute of Technology Palakkad, shared a post on LinkedIn and about a recent article he and his colleagues co-authored, adding:
“An editorial commentary in Nature Reviews Cardiology, Nature Portfolio, co-authored with Julie Rayes, discusses the mechanisms underlying Vaccine-induced immune thrombotic thrombocytopenia, a rare complication of adenoviral vector-based COVID-19 vaccines.
An elegant study by the groups of J. J. Wang and Andreas Greinacher demonstrates that VITT arises from molecular mimicry between platelet factor 4 PF4 and adenoviral core protein VII.
In genetically predisposed individuals carrying IGLV3-21 star 02 or star 03 alleles, a key somatic mutation K31E in the IgG light chain redirects antiviral immunity toward pathogenic anti PF4 responses, triggering platelet activation and thrombosis.
This work provides a compelling example of how genetic background and somatic hypermutation converge to drive autoimmunity, and opens new avenues for designing safer adenoviral vector platforms.”
Title: Solving the mystery of vaccine-induced immune thrombocytopenia and thrombosis
Authors: Julie Rayes, Jagadeesh Bayry
Read the Full Article on Nature Reviews Cardiology.

Title: Adenoviral Inciting Antigen and Somatic Hypermutation in VITT
Authors: Jing Jing Wang, Linda Schönborn, Theodore E. Warkentin, Luisa Müller, Thomas Thiele, Lena Ulm, Uwe Völker, Sabine Ameling, Sören Franzenburg, Lars Kaderali, Ana Tzvetkova, Alex Colella, Tim Chataway, Chee Wee Tan, Bridie Armour, Alexander Troelnikov, Lucy Rutten, James McCluskey, Roland Zahn, Tom P. Gordon, Andreas Greinacher
Read the Full Article on The New England Journal Of Medicine.

Stay updated on all scientific advances with Hemostasis Today.
-
Nov 15, 2026, 23:30Eshal Amir: Factor XI Inhibitors in AFib and Aortic Mortality Trends
-
Nov 15, 2026, 23:19Hamza Bashir: Adding Endovascular Therapy to Anticoagulation Cuts Moderate-to-Severe PTS in Half
-
Nov 15, 2026, 23:06Lanre Tunji-Ajayi: 2 Days of Deliberative Dialogue Hosted by the Network of Rare Blood Disorder Organizations
-
Nov 15, 2026, 23:00Fanny Delettre: Looking Back at Volunteer Blood Donor Friends Day
-
Nov 15, 2026, 20:56Victoria Adedoyin Adisa-Thomas: What I Learned About SCD During My Genetic Counselling Rotation
-
Nov 15, 2026, 20:55Martin Holst Lange: One Step Closer to a Potential New Treatment for Sickle Cell Disease
-
Nov 15, 2026, 20:53Bontha Babu: Health-Related Quality of Life Among Adults with Sickle Cell Disease in India
-
Nov 15, 2026, 20:52Miguel Ángel Herrera Rojas: A First-Line ITP Approach Presented at ASH in 2013 Now Reflected in the 2026 Guidelines
-
Nov 15, 2026, 20:50Asmaa Beltagy: Efficacy and Safety of Eltrombopag in SLE-Associated Immune Thrombocytopenia